ProPhase Labs (NASDAQ:PRPH – Get Free Report) was upgraded by equities research analysts at StockNews.com to a “sell” rating in a report released on Wednesday.
ProPhase Labs Price Performance
Shares of PRPH traded down $0.06 during midday trading on Wednesday, hitting $4.26. 23,118 shares of the company traded hands, compared to its average volume of 43,527. The firm has a 50 day moving average of $4.92 and a 200-day moving average of $5.10. ProPhase Labs has a 52 week low of $4.05 and a 52 week high of $7.59. The stock has a market cap of $81.28 million, a price-to-earnings ratio of -3.94 and a beta of -0.18. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.73 and a current ratio of 1.88.
ProPhase Labs (NASDAQ:PRPH – Get Free Report) last issued its earnings results on Thursday, May 9th. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.21. ProPhase Labs had a negative net margin of 82.18% and a negative return on equity of 44.96%. The business had revenue of $3.63 million for the quarter, compared to analyst estimates of $9.86 million. During the same period last year, the company posted $0.03 earnings per share. On average, analysts forecast that ProPhase Labs will post -0.82 EPS for the current fiscal year.
Hedge Funds Weigh In On ProPhase Labs
ProPhase Labs Company Profile
ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.
Read More
- Five stocks we like better than ProPhase Labs
- How Investors Can Find the Best Cheap Dividend Stocks
- Stock Impact: McDonald’s Price War with Starbucks, Wendy’s
- Most active stocks: Dollar volume vs share volume
- General Mills Q4 Sales Miss Expectations, Triggering Stock Drop
- How to Calculate Options Profits
- Enovix Stock Rises 35% in Short-Squeeze: This Rally Has Legs
Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.